Growth hormone release: Interaction of increased extracellular calcium and somatostatin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

These studies were designed to examine the effects of extracellular calcium ion (Ca+plus;) concentration upon basal and dibutyryl (db) cAMP or potassium ion (K+)-stimulated release of growth hormone (GH) and to determine whether increased extracellular Ca+plus; can overcome somatostatin (SRIF) -inhibited release of stored rGH in parallel with its reported effect upon SRIF inhibition of stimulated insulin and glucagon release. Experiments were performed in vitro using prelabeled rat pituitary fragments in a perifusion, specific immunoprecipitation system designed to limit observations to release of stored hormone from viable cells. Increased (up to 5.4 mM) extracellular Ca+plus; inhibits basal and dbcAMP-stimulated release of stored, prelabeled [3H]rGH in parallel with the effects of SRIF: post-inhibition rebound, dose responsivity, and differential effect upon early and late dbcAMP-stimulated release of stored [3H]rGH. Increased (21 mM) extracellular K+ interferes with both Ca+plus; -and SRIF-inhibited early dbcAMP-stimulated release of stored [3H]rGH. The combination of increased extracellular Ca+plus; and SRIF inhibits basal release of stored [3H]rGH more than either agent alone and during dbcAMP stimulation, rebound release of stored [3H]rGH follows withdrawal of either inhibitor despite continuation of the other. This rebound release is enhanced when both inhibitors are withdrawn simultaneously. Conclusions: (a) the inhibition of stored rGH release induced by increased extracellular Ca+plus; and SRIF occurs through at least partially independent mechanisms, and (b) increased extracellular Ca+plus; does not reverse SRIF inhibition of stimulated rGH release from prelabeled intracellular storage, in contrast with observations in the pancreatic islet.

Original languageEnglish (US)
Pages (from-to)69-92
Number of pages24
JournalEndocrine Research
Volume12
Issue number1
DOIs
StatePublished - Jan 1 1986

Fingerprint

Somatostatin
Growth Hormone
Ions
Calcium
Glucagon
Islets of Langerhans
Immunoprecipitation
Potassium
Hormones
Insulin
In Vitro Techniques

ASJC Scopus subject areas

  • Endocrinology

Cite this

Growth hormone release : Interaction of increased extracellular calcium and somatostatin. / Stachura, M. E.

In: Endocrine Research, Vol. 12, No. 1, 01.01.1986, p. 69-92.

Research output: Contribution to journalArticle

@article{9d559773bfc945d4b43c22818a6cdb12,
title = "Growth hormone release: Interaction of increased extracellular calcium and somatostatin",
abstract = "These studies were designed to examine the effects of extracellular calcium ion (Ca+plus;) concentration upon basal and dibutyryl (db) cAMP or potassium ion (K+)-stimulated release of growth hormone (GH) and to determine whether increased extracellular Ca+plus; can overcome somatostatin (SRIF) -inhibited release of stored rGH in parallel with its reported effect upon SRIF inhibition of stimulated insulin and glucagon release. Experiments were performed in vitro using prelabeled rat pituitary fragments in a perifusion, specific immunoprecipitation system designed to limit observations to release of stored hormone from viable cells. Increased (up to 5.4 mM) extracellular Ca+plus; inhibits basal and dbcAMP-stimulated release of stored, prelabeled [3H]rGH in parallel with the effects of SRIF: post-inhibition rebound, dose responsivity, and differential effect upon early and late dbcAMP-stimulated release of stored [3H]rGH. Increased (21 mM) extracellular K+ interferes with both Ca+plus; -and SRIF-inhibited early dbcAMP-stimulated release of stored [3H]rGH. The combination of increased extracellular Ca+plus; and SRIF inhibits basal release of stored [3H]rGH more than either agent alone and during dbcAMP stimulation, rebound release of stored [3H]rGH follows withdrawal of either inhibitor despite continuation of the other. This rebound release is enhanced when both inhibitors are withdrawn simultaneously. Conclusions: (a) the inhibition of stored rGH release induced by increased extracellular Ca+plus; and SRIF occurs through at least partially independent mechanisms, and (b) increased extracellular Ca+plus; does not reverse SRIF inhibition of stimulated rGH release from prelabeled intracellular storage, in contrast with observations in the pancreatic islet.",
author = "Stachura, {M. E.}",
year = "1986",
month = "1",
day = "1",
doi = "10.1080/07435808609023654",
language = "English (US)",
volume = "12",
pages = "69--92",
journal = "Endocrine Research",
issn = "0743-5800",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Growth hormone release

T2 - Interaction of increased extracellular calcium and somatostatin

AU - Stachura, M. E.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - These studies were designed to examine the effects of extracellular calcium ion (Ca+plus;) concentration upon basal and dibutyryl (db) cAMP or potassium ion (K+)-stimulated release of growth hormone (GH) and to determine whether increased extracellular Ca+plus; can overcome somatostatin (SRIF) -inhibited release of stored rGH in parallel with its reported effect upon SRIF inhibition of stimulated insulin and glucagon release. Experiments were performed in vitro using prelabeled rat pituitary fragments in a perifusion, specific immunoprecipitation system designed to limit observations to release of stored hormone from viable cells. Increased (up to 5.4 mM) extracellular Ca+plus; inhibits basal and dbcAMP-stimulated release of stored, prelabeled [3H]rGH in parallel with the effects of SRIF: post-inhibition rebound, dose responsivity, and differential effect upon early and late dbcAMP-stimulated release of stored [3H]rGH. Increased (21 mM) extracellular K+ interferes with both Ca+plus; -and SRIF-inhibited early dbcAMP-stimulated release of stored [3H]rGH. The combination of increased extracellular Ca+plus; and SRIF inhibits basal release of stored [3H]rGH more than either agent alone and during dbcAMP stimulation, rebound release of stored [3H]rGH follows withdrawal of either inhibitor despite continuation of the other. This rebound release is enhanced when both inhibitors are withdrawn simultaneously. Conclusions: (a) the inhibition of stored rGH release induced by increased extracellular Ca+plus; and SRIF occurs through at least partially independent mechanisms, and (b) increased extracellular Ca+plus; does not reverse SRIF inhibition of stimulated rGH release from prelabeled intracellular storage, in contrast with observations in the pancreatic islet.

AB - These studies were designed to examine the effects of extracellular calcium ion (Ca+plus;) concentration upon basal and dibutyryl (db) cAMP or potassium ion (K+)-stimulated release of growth hormone (GH) and to determine whether increased extracellular Ca+plus; can overcome somatostatin (SRIF) -inhibited release of stored rGH in parallel with its reported effect upon SRIF inhibition of stimulated insulin and glucagon release. Experiments were performed in vitro using prelabeled rat pituitary fragments in a perifusion, specific immunoprecipitation system designed to limit observations to release of stored hormone from viable cells. Increased (up to 5.4 mM) extracellular Ca+plus; inhibits basal and dbcAMP-stimulated release of stored, prelabeled [3H]rGH in parallel with the effects of SRIF: post-inhibition rebound, dose responsivity, and differential effect upon early and late dbcAMP-stimulated release of stored [3H]rGH. Increased (21 mM) extracellular K+ interferes with both Ca+plus; -and SRIF-inhibited early dbcAMP-stimulated release of stored [3H]rGH. The combination of increased extracellular Ca+plus; and SRIF inhibits basal release of stored [3H]rGH more than either agent alone and during dbcAMP stimulation, rebound release of stored [3H]rGH follows withdrawal of either inhibitor despite continuation of the other. This rebound release is enhanced when both inhibitors are withdrawn simultaneously. Conclusions: (a) the inhibition of stored rGH release induced by increased extracellular Ca+plus; and SRIF occurs through at least partially independent mechanisms, and (b) increased extracellular Ca+plus; does not reverse SRIF inhibition of stimulated rGH release from prelabeled intracellular storage, in contrast with observations in the pancreatic islet.

UR - http://www.scopus.com/inward/record.url?scp=0022638591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022638591&partnerID=8YFLogxK

U2 - 10.1080/07435808609023654

DO - 10.1080/07435808609023654

M3 - Article

C2 - 2870919

AN - SCOPUS:0022638591

VL - 12

SP - 69

EP - 92

JO - Endocrine Research

JF - Endocrine Research

SN - 0743-5800

IS - 1

ER -